JOHN VIERLING

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address6620 MAIN
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Surgery
    DivisionSurgery-Transplant Division


    Collapse Overview 
    Collapse overview
    Dr. John M. Vierling’s primary research interests are the immunopathogenic mechanisms involved in hepatobiliary injury caused by viral infection, autoimmunity, alloimmunity, and non-alcoholic fatty liver disease. Dr. Vierling’s basic science laboratory investigations have used murine models to study the immunopathogenesis of non-suppurative destructive cholangitis, which destroys bile ducts in primary biliary cirrhosis, an autoimmune liver disease, as well as in two alloimmune diseases, hepatic allograft rejection and chronic graft-versus-host disease.

    By emphasizing a "laboratory bench to bedside" philosophy, Dr. Vierling has also been active in the design and execution of clinical therapeutic trials of antiviral agents for treatment of hepatitis B and C infections in patients before and after liver transplantation, trials of immunosuppressive drugs in liver transplantation and autoimmune liver diseases, trials of new therapies for hepatic encephalopathy and antifibrotic agents to prevent or reverse cirrhosis. Dr. Vierling is the author of numerous research publications, reviews and chapters on these topics.

    Dr. Vierling directs Advanced Liver Therapies, a clinical research unit devoted to hepatobiliary diseases. He and his research staff are conducting phase 1-3 studies of diagnostics and therapies in chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, non-alcoholic fatty liver disease, anti-fibrotic therapy to prevent cirrhosis, hepatic encephalopathy, and measurement of hepatocellular function using 13C-labeled compounds.

    Dr. Vierling is board certified in internal medicine and gastroenterology and a Fellow of the American College of Physicians. He created a liver transplant program at the University of olorado Health Sciences Center.

    Collapse Research 
    Collapse research activities and funding
    R01DK033883     (VIERLING, JOHN M)Aug 1, 1986 - Jul 31, 1993
    NIH/NIDDK
    HEPATIC LESIONS IN MURINE CHRONIC GRAFT-VS-HOST DISEASE
    Role: Principal Investigator

    R01DK053945     (VIERLING, JOHN M)Mar 1, 1999 - Feb 28, 2002
    NIH/NIDDK
    HEPATIC LESIONS IN MURINE CHRONIC GRAFT VS HOST DISEASE
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354. PMID: 33484775.
      Citations: 2     Fields:    
    2. Roepe IG, Vierling JM, Goss JA, Miloh T. Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study. J Pediatr Gastroenterol Nutr. 2021 01 01; 72(1):101-107. PMID: 32796427.
      Citations:    Fields:    Translation:Humans
    3. Nangia G, Vierling JM, Kwo P, Brown DD, Klopfer SO, Robertson MN, Haber BA, Reddy KR. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. J Viral Hepat. 2020 11; 27(11):1222-1233. PMID: 32594612.
      Citations: 1     Fields:    Translation:HumansCells
    4. Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020 11; 114:102514. PMID: 32768244.
      Citations: 3     Fields:    Translation:HumansAnimals
    5. Zhang T, Dunson J, Kanwal F, Galvan NTN, Vierling JM, O'Mahony C, Goss JA, Rana A. Trends in Outcomes for Marginal Allografts in Liver Transplant. JAMA Surg. 2020 Aug 05. PMID: 32777009.
      Citations: 3     Fields:    
    6. Zhang T, Dunson J, Kanwal F, Galvan NTN, Vierling JM, O'Mahony C, Goss JA, Rana A. Trends in Outcomes for Marginal Allografts in Liver Transplant. JAMA Surg. 2020 Aug 05. PMID: 32936250.
      Citations: 1     Fields:    
    7. Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis DN, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology. 2020 08; 72(2):753-769. PMID: 32500593.
      Citations: 4     Fields:    Translation:Humans
    8. Galvan NTN, Moreno NF, Garza JE, Bourgeois S, Hemmersbach-Miller M, Murthy B, Timmins K, O'Mahony CA, Anton J, Civitello A, Garcha P, Loor G, Liao K, Shaffi A, Vierling J, Stribling R, Rana A, Goss JA. Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic. Am J Transplant. 2020 11; 20(11):3113-3122. PMID: 32524743.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    9. Rana A, Price MB, Barrett SC, Lai J, Bakhtiyar SS, Kanwal F, Vierling J, Wu M, Galvan NT, Goss J. Aggressive utilization of liver allografts: Improved outcomes over time. Clin Transplant. 2020 07; 34(7):e13860. PMID: 32198898.
      Citations:    Fields:    Translation:Humans
    10. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020 08; 72(2):671-722. PMID: 31863477.
      Citations: 59     Fields:    Translation:Humans
    11. Zhang T, Price MB, Bravo N, Villarreal JA, Kueht ML, Vierling JM, Cotton R, Galvan T, O'Mahony CA, Goss JA, Rana A. Combined Lung-Liver and Delayed Kidney Transplantation for Cystic Fibrosis Clinical Approach and Outcome: A Case Report. Transplant Proc. 2020 Nov; 52(9):2824-2826. PMID: 32389488.
      Citations: 2     Fields:    Translation:Humans
    12. Rana A, Joshi M, Price MB, Ganni S, Bakhtiyar SS, Vierling JM, Galvan NT, Cotton RT, O'Mahony CA, Kanwal F, Goss JA. A learning curve in using orphan liver allografts for transplantation. Clin Transplant. 2020 04; 34(4):e13821. PMID: 32034946.
      Citations:    Fields:    Translation:Humans
    13. Nichols TJ, Price MB, Villarreal JA, Bakhtiyar SS, Vierling JM, Cotton R, Galvan T, O'Mahony CA, Goss JA, Rana A. Most pediatric transplant centers are low volume, adult-focused, and in proximity to higher volume pediatric centers. J Pediatr Surg. 2020 Aug; 55(8):1667-1672. PMID: 31753609.
      Citations:    Fields:    Translation:Humans
    14. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun. 2019 12; 105:102328. PMID: 31548157.
      Citations: 13     Fields:    Translation:Humans
    15. Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 07; 101:26-34. PMID: 31027870.
      Citations: 10     Fields:    Translation:Humans
    16. Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, Wu MF, Yoeli D, Kueht M, Mindikoglu AL, Sussman NL, Galván NT, Cotton RT, O'Mahony CA, Goss JA. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg. 2019 01; 269(1):20-27. PMID: 29303806.
      Citations: 12     Fields:    Translation:Humans
    17. Lawitz E, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, Bennett M, Kemmer N, Morelli G, Zha J, Wang D, Shulman NS, Cohen DE, Reddy KR. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney Int Rep. 2019 Feb; 4(2):257-266. PMID: 30775622.
      Citations: 4     
    18. Rana A, Sigireddi RR, Halazun KJ, Kothare A, Wu MF, Liu H, Kueht ML, Vierling JM, Sussman NL, Mindikoglu AL, Miloh T, Galvan NTN, Cotton RT, O'Mahony CA, Goss JA. Predicting Liver Allograft Discard: The Discard Risk Index. Transplantation. 2018 09; 102(9):1520-1529. PMID: 29485514.
      Citations: 4     Fields:    Translation:Humans
    19. Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC, Vierling JM, Nguyen MH. Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterol. 2018; 5(1):e000203. PMID: 29755758.
      Citations: 8     
    20. Zamor PJ, Vierling J, Ghalib R, Luketic V, Ravendhran N, Balart L, Robertson M, Hwang P, Hanna GJ, Nguyen BY, Barr E, Talwani R, Pearlman B. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871. PMID: 29695828.
      Citations: 1     Fields:    Translation:HumansCells
    21. Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ. Autoimmune hepatitis. Nat Rev Dis Primers. 2018 04 12; 4:18017. PMID: 29644994.
      Citations: 42     Fields:    Translation:HumansCellsPHPublic Health
    22. Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2018 05; 3(5):363-370. PMID: 29644978.
      Citations: 3     Fields:    Translation:Humans
    23. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME. Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol. 2018 Apr 01; 36(10):959-967. PMID: 29447061.
      Citations: 6     Fields:    
    24. Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675. PMID: 29392554.
      Citations: 7     Fields:    Translation:Humans
    25. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369. PMID: 29365309.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    26. Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688. PMID: 29344726.
      Citations: 8     Fields:    Translation:HumansCells
    27. Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47. PMID: 29291380.
      Citations: 8     Fields:    Translation:Humans
    28. Rana A, Witte ED, Halazun KJ, Sood GK, Mindikoglu AL, Sussman NL, Vierling JM, Kueht ML, Galvan NTN, Cotton RT, O'Mahony CA, Goss JA. Liver transplant length of stay (LOS) index: A novel predictive score for hospital length of stay following liver transplantation. Clin Transplant. 2017 Dec; 31(12). PMID: 29044759.
      Citations: 4     Fields:    Translation:Humans
    29. Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, Vierling JM, Hirschfield GM. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2018 02; 16(2):278-287.e7. PMID: 28993258.
      Citations: 10     Fields:    Translation:Humans
    30. Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM. Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726. PMID: 28818518.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    31. Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823. PMID: 28802814.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    32. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146. PMID: 28564569.
      Citations: 122     Fields:    Translation:HumansCellsCTClinical Trials
    33. Goss M, Reese J, Kueht M, Vierling JM, Mindikoglu AL, Sussman NL, Kaplan B, Wood RP, Rana AA. A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association? Liver Transpl. 2017 05; 23(5):698-700. PMID: 28295986.
      Citations: 3     Fields:    Translation:Humans
    34. Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017 03; 45(5):723-732. PMID: 28004405.
      Citations: 18     Fields:    Translation:Humans
    35. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27740516.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    36. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26385706.
      Citations: 20     Fields:    Translation:Humans
    37. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25467560.
      Citations: 101     Fields:    Translation:HumansCellsCTClinical Trials
    38. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25703086.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    39. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26195210.
      Citations: 2     Fields:    Translation:Humans
    40. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26416194.
      Citations: 13     Fields:    Translation:Humans
    41. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30833848.
      Citations: 1     Fields:    Translation:Humans
    42. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30892921.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    43. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29881823.
      Citations: 17     
    44. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31185813.
      Citations:    Fields:    Translation:Humans
    45. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32025330.
      Citations:    
    46. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32248587.
      Citations:    Fields:    Translation:HumansPHPublic Health
    47. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33729047.
      Citations:    Fields:    Translation:Humans
    48. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 34416083.
      Citations:    Fields:    
    49. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32707342.
      Citations: 1     Fields:    Translation:Humans
    50. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10895437.
      Citations:    Fields:    Translation:HumansCells
    51. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22334369.
      Citations: 20     Fields:    Translation:HumansCells
    52. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11155147.
      Citations: 11     Fields:    Translation:HumansCells
    53. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23406826.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    54. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 4083353.
      Citations: 1     Fields:    Translation:Animals
    55. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9230022.
      Citations: 9     Fields:    Translation:Humans
    56. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20147697.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    57. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6678435.
      Citations:    Fields:    Translation:Humans
    58. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3568953.
      Citations:    Fields:    Translation:Humans
    59. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16250040.
      Citations: 164     Fields:    Translation:Humans
    60. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22933131.
      Citations: 11     Fields:    Translation:HumansAnimalsPHPublic Health
    61. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9425940.
      Citations: 62     Fields:    Translation:HumansCells
    62. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1531454.
      Citations:    Fields:    Translation:AnimalsCells
    63. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8623212.
      Citations:    Fields:    Translation:Humans
    64. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14586901.
      Citations: 3     Fields:    Translation:Humans
    65. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8813166.
      Citations:    Fields:    Translation:Humans
    66. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3905558.
      Citations: 18     Fields:    Translation:HumansCells
    67. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16509862.
      Citations: 11     Fields:    Translation:Humans
    68. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18556418.
      Citations: 19     Fields:    Translation:AnimalsCells
    69. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2799935.
      Citations: 3     Fields:    Translation:Animals
    70. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9346770.
      Citations: 6     Fields:    Translation:HumansCells
    71. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23180996.
      Citations: 36     Fields:    Translation:HumansCells
    72. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16496229.
      Citations: 39     Fields:    Translation:Humans
    73. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15062200.
      Citations: 6     Fields:    Translation:Humans
    74. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22117641.
      Citations: 16     Fields:    Translation:Humans
    75. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6363265.
      Citations: 3     Fields:    Translation:Humans
    76. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 332716.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    77. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10895440.
      Citations:    Fields:    Translation:HumansPHPublic Health
    78. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9346758.
      Citations: 7     Fields:    Translation:Humans
    79. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12891528.
      Citations: 49     Fields:    Translation:Humans
    80. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23348636.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    81. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24209764.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    82. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23847109.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    83. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24815863.
      Citations: 15     Fields:    Translation:Humans
    84. Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 01; 152(1):164-175.e4. PMID: 27720838.
      Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
    85. Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016 Nov; 10(6):909-915. PMID: 27649967.
      Citations: 14     Fields:    Translation:Humans
    86. Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016; 5(1):1365. PMID: 27588258.
      Citations: 2     
    87. Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016 Dec; 75:6-19. PMID: 27502148.
      Citations: 26     Fields:    Translation:Humans
    88. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505. PMID: 26754432.
      Citations: 116     Fields:    Translation:HumansCTClinical Trials
    89. Landis CS, Ghabril M, Rustgi V, Di Bisceglie AM, Maliakkal B, Rockey DC, Vierling JM, Bajaj J, Rowell R, Santoro M, Enriquez A, Jurek M, Mokhtarani M, Coakley DF, Scharschmidt BF. Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 06; 61(6):1728-34. PMID: 26781427.
      Citations: 4     Fields:    Translation:Humans
    90. Vierling JM, Mokhtarani M, Brown RS, Mantry P, Rockey DC, Ghabril M, Rowell R, Jurek M, Coakley DF, Scharschmidt BF. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016 06; 14(6):903-906.e1. PMID: 26707685.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    91. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Clin Res Hepatol Gastroenterol. 2015 Oct; 39(5):e57-9. PMID: 26433440.
      Citations: 13     Fields:    Translation:Humans
    92. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Dig Liver Dis. 2015 Nov; 47(11):924-6. PMID: 26419788.
      Citations: 6     Fields:    Translation:Humans
    93. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1867-9. PMID: 26386643.
      Citations: 4     Fields:    Translation:Humans
    94. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. J Hepatol. 2015 Nov; 63(5):1285-7. PMID: 26385765.
      Citations: 21     Fields:    Translation:Humans
    95. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology. 2015 Nov; 62(5):1620-2. PMID: 26372460.
      Citations: 43     Fields:    Translation:Humans
    96. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gut. 2015 Nov; 64(11):1671-2. PMID: 26374822.
      Citations: 9     Fields:    Translation:Humans
    97. Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8. PMID: 26353843.
      Citations: 7     Fields:    Translation:HumansCells
    98. Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2088-108. PMID: 26284592.
      Citations: 12     Fields:    Translation:Humans
    99. Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44. PMID: 26238707.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    100. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44. PMID: 25942724.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    101. Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med. 2015 Jun; 9(2):187-219. PMID: 25749982.
      Citations: 13     Fields:    Translation:Humans
    102. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302. PMID: 25239078.
      Citations: 10     Fields:    Translation:HumansCells
    103. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56. PMID: 25080450.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    104. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46. PMID: 25064437.
      Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
    105. Khaderi S, Khan R, Safdar Z, Stribling R, Vierling JM, Goss JA, Sussman NL. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014 Jun; 20(6):724-7. PMID: 24648168.
      Citations: 11     Fields:    Translation:Humans
    106. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9. PMID: 24747798.
      Citations: 9     Fields:    Translation:Humans
    107. Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6. PMID: 24727022.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    108. Vierling JM. Immunopathogenesis: Insights for current and future therapies. Clin Liver Dis (Hoboken). 2014 Feb; 3(2):24-28. PMID: 31236265.
      Citations:    
    109. Lucey MR, Vierling JM. Clinical presentation and natural history of autoimmune hepatitis. Clin Liver Dis (Hoboken). 2014 Jan; 3(1):9-11. PMID: 30992880.
      Citations: 1     
    110. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am. 2014 Jan; 98(1):17-38. PMID: 24266912.
      Citations: 9     Fields:    Translation:HumansCells
    111. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56. PMID: 24362076.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    112. Raza A, Vierling J, Hussain KB. Genetics of drug-induced hepatotoxicity toxicity in Gilbert's syndrome. Am J Gastroenterol. 2013 Dec; 108(12):1936-7. PMID: 24300875.
      Citations:    Fields:    Translation:Humans
    113. Manns MP, McCone J, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19. PMID: 24118703.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    114. Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, Schulze A, Longo N, Bartley J, Berquist W, Gallagher R, Smith W, McCandless SE, Harding C, Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Dickinson K, Moors T, Norris C, Coakley D, Milikien DA, Nagamani SC, Lemons C, Lee B, Scharschmidt BF. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 2013 Dec; 110(4):446-53. PMID: 24144944.
      Citations: 8     Fields:    Translation:Humans
    115. Pinto-Patarroyo GP, Rytting ME, Vierling JM, Suarez-Almazor ME. Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections. BMJ Case Rep. 2013 Aug 13; 2013. PMID: 23943807.
      Citations: 7     Fields:    Translation:Humans
    116. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23. PMID: 23359491.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    117. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Erratum to: Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2013 Apr; 21(4):1211. PMID: 23354554.
      Citations:    
    118. Cobb B, Pockros PJ, Vilchez RA, Vierling JM. HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol. 2013 Apr; 108(4):471-5. PMID: 23552304.
      Citations: 13     Fields:    Translation:HumansCells
    119. Ghabril M, Zupanets IA, Vierling J, Mantry P, Rockey D, Wolf D, O'Shea R, Dickinson K, Gillaspy H, Norris C, Coakley DF, Mokhtarani M, Scharschmidt BF. Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration. Clin Pharmacol Drug Dev. 2013 Jul; 2(3):278-84. PMID: 27121790.
      Citations: 8     Fields:    
    120. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7. PMID: 23499440.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    121. Vierling JM. Hepatitis C virus viral assays in the direct-acting antiviral era. Clin Liver Dis. 2013 Feb; 17(1):27-45. PMID: 23177281.
      Citations: 2     Fields:    Translation:HumansCells
    122. Selmi C, Ceribelli A, Vierling JM. Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis. Semin Immunopathol. 2013 Jan; 35(1):1-5. PMID: 23250654.
      Citations:    Fields:    Translation:HumansCells
    123. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87. PMID: 23183529.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    124. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5. PMID: 23064222.
      Citations: 24     Fields:    Translation:HumansCells
    125. Vierling JM. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep. 2012 Feb; 14(1):25-36. PMID: 22179843.
      Citations: 6     Fields:    Translation:Humans
    126. Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012 Feb; 55(2):512-21. PMID: 22006563.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    127. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011 Aug; 15(3):515-36. PMID: 21867934.
      Citations: 4     Fields:    Translation:Humans
    128. Nguyen NT, Vierling JM. Acute liver failure. Curr Opin Organ Transplant. 2011 Jun; 16(3):289-96. PMID: 21519261.
      Citations: 6     Fields:    Translation:Humans
    129. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17. PMID: 21449784.
      Citations: 485     Fields:    Translation:HumansCellsCTClinical Trials
    130. Merwat SN, Vierling JM. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis. 2011 Feb; 15(1):131-52. PMID: 21111997.
      Citations: 4     Fields:    Translation:HumansCells
    131. Vierling JM. Autoimmune hepatitis and antigen-specific T regulatory cells: when can we send in the regulators? Hepatology. 2011 Feb; 53(2):385-8. PMID: 21274860.
      Citations: 6     Fields:    Translation:HumansCells
    132. Vierling JM, Hreha G, Wang H, Braun M. The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease. Trans Am Clin Climatol Assoc. 2011; 122:326-35. PMID: 21686235.
      Citations: 3     Fields:    Translation:AnimalsCells
    133. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32. PMID: 20564352.
      Citations: 92     Fields:    Translation:HumansCellsCTClinical Trials
    134. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16. PMID: 20692693.
      Citations: 193     Fields:    Translation:Humans
    135. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun; 51(6):2193-213. PMID: 20513004.
      Citations: 344     Fields:    Translation:Humans
    136. Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 2007 Dec; 46(6):1836-43. PMID: 18027862.
      Citations: 9     Fields:    Translation:Humans
    137. Vierling JM. The immunology of hepatitis B. Clin Liver Dis. 2007 Nov; 11(4):727-59, vii-viii. PMID: 17981227.
      Citations: 23     Fields:    Translation:HumansCells
    138. Choi WC, Arnaout WC, Villamil FG, Demetriou AA, Vierling JM. Comparison of the applicability of two prognostic scoring systems in patients with fulminant hepatic failure. Korean J Intern Med. 2007 Jun; 22(2):93-100. PMID: 17616024.
      Citations: 5     Fields:    Translation:Humans
    139. Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant. 2007 May; 7(5):1265-70. PMID: 17359503.
      Citations: 28     Fields:    Translation:Humans
    140. Barshes NR, Hacker CS, Freeman RB, Vierling JM, Goss JA. Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocation. J Contemp Health Law Policy. 2007; 23(2):200-30. PMID: 17642381.
      Citations:    Fields:    Translation:Humans
    141. Freeman RB, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S128-36. PMID: 17123284.
      Citations: 33     Fields:    Translation:Humans
    142. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, Zhang E, Vierling J, Frost A. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006 Sep; 6(9):2177-82. PMID: 16796721.
      Citations: 25     Fields:    Translation:Humans
    143. Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006 Jun; 35(2):463-86. PMID: 16880075.
      Citations: 4     Fields:    Translation:Humans
    144. Saab S, Nguyen S, Ibrahim A, Vierling JM, Tong MJ. Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006 Feb; 40(2):156-61. PMID: 16394878.
      Citations: 8     Fields:    Translation:Humans
    145. Shackleton CR, Vierling JM, Nissen N, Martin P, Poordad F, Tran T, Colquhoun SD. Morbidity in live liver donors: standards-based adverse event reporting further refined. Arch Surg. 2005 Sep; 140(9):888-95; discussion 895-6. PMID: 16172298.
      Citations: 4     Fields:    Translation:Humans
    146. Vierling JM. Future Treatment Options in PBC. Semin Liver Dis. 2005 Aug; 25(3):347-63. PMID: 16143950.
      Citations: 3     Fields:    Translation:HumansCells
    147. Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev. 2006 Jan; 5(1):1-9. PMID: 16338205.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    148. Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci. 2005; 2(1):41-49. PMID: 15968339.
      Citations: 7     Fields:    
    149. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005 Jan; 39(1):75-7. PMID: 15599217.
      Citations: 16     Fields:    Translation:Humans
    150. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005 Jan; 41(1):207-15. PMID: 15690485.
      Citations: 14     Fields:    Translation:Humans
    151. Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004 Sep; 28(9):1204-11. PMID: 15316320.
      Citations: 15     Fields:    Translation:Humans
    152. Papadakis KA, Matuk R, Abreu MT, Vasiliauskas EA, Fleshner PR, Lechago J, Tran T, Poordad FF, Martin P, Vierling J, Targan SR. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90. PMID: 15306609.
      Citations: 1     Fields:    Translation:Humans
    153. Xu J, Lee G, Wang H, Vierling JM, Maher JJ. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41. PMID: 15130876.
      Citations: 24     Fields:    Translation:AnimalsCells
    154. Firpi RJ, Tran TT, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004 May 01; 19(9):1033-9. PMID: 15113371.
      Citations: 5     Fields:    Translation:Humans
    155. Bunnapradist S, Fabrizi F, Vierling J, Martin R, Moudgil A, Kamil E, Jordan S. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs. 2002 Dec; 25(12):1189-93. PMID: 12518964.
      Citations: 1     Fields:    Translation:HumansCells
    156. Collisson EA, Nourmand H, Fraiman MH, Cooper CB, Bellamy PE, Farmer DG, Vierling JM, Ghobrial RM, Busuttil RW. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl. 2002 Oct; 8(10):925-31. PMID: 12360435.
      Citations: 12     Fields:    Translation:Humans
    157. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002 Sep; 123(3):719-27. PMID: 12198698.
      Citations: 50     Fields:    Translation:HumansCells
    158. Shackleton CR, Colquhoun SD, Vierling JM. Transplantation of the right hepatic lobe. N Engl J Med. 2002 Aug 22; 347(8):615-8; author reply 615-8. PMID: 12195588.
      Citations:    Fields:    Translation:Humans
    159. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002 Aug; 6(3):825-50, ix. PMID: 12362583.
      Citations: 7     Fields:    Translation:HumansCells
    160. Amankonah TD, Strom CB, Vierling JM, Petrovic LM. Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease. Am J Gastroenterol. 2001 Aug; 96(8):2520-2. PMID: 11513216.
      Citations: 5     Fields:    Translation:Humans
    161. Vierling JM. Animal models for primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001 Aug; 15(4):591-610. PMID: 11492970.
      Citations: 12     Fields:    Translation:HumansAnimals
    162. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001 Jun; 7(6):513-7. PMID: 11443579.
      Citations: 19     Fields:    Translation:Humans
    163. Vierling JM, Teperman LW, Lake JR, Perrillo RP, Peters M, Fried M, Schiff ER. Case studies of the hepatitis B patient: a panel discussion. Semin Liver Dis. 2000; 20 Suppl 1:29-35. PMID: 10895442.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    164. Vierling JM, Teperman LW. Introduction to hepatitis B transplantation. Semin Liver Dis. 2000; 20 Suppl 1:1-2. PMID: 10895436.
      Citations:    Fields:    Translation:HumansPHPublic Health
    165. Vierling JM. Autoimmune cholangiopathy. Clin Liver Dis. 1999 Aug; 3(3):571-84. PMID: 11291239.
      Citations:    Fields:    Translation:HumansCells
    166. Hreha G, Jefferson DM, Yu CH, Grubman SA, Alsabeh R, Geller SA, Vierling JM. Immortalized intrahepatic mouse biliary epithelial cells: immunologic characterization and immunogenicity. Hepatology. 1999 Aug; 30(2):358-71. PMID: 10421641.
      Citations: 5     Fields:    Translation:AnimalsCells
    167. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S1-S20. PMID: 10431013.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    168. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999 Jan; 94(1):241-8. PMID: 9934764.
      Citations: 28     Fields:    Translation:Humans
    169. Goldman DE, Colquhoun SD, Ghobrial RM, Arnaout WS, Farmer DG, Markmann JF, Shackleton CR, Vierling JM, Busuttil RW. Mycotic aneurysm of arterial conduit presenting as massive upper gastrointestinal hemorrhage after liver transplantation. Liver Transpl Surg. 1998 Sep; 4(5):435-6. PMID: 9724483.
      Citations:    Fields:    Translation:Humans
    170. Coffman KL, Sher L, Hoffman A, Rojter S, Folk P, Cramer DV, Vierling J, Villamel F, Podesta L, Demetriou A, Makowka L. Survey results of transplant patients' attitudes on xenografting. Psychosomatics. 1998 Jul-Aug; 39(4):379-83. PMID: 9691708.
      Citations: 1     Fields:    Translation:HumansAnimals
    171. Watanabe FD, Shackleton CR, Cohen SM, Goldman DE, Arnaout WS, Hewitt W, Colquhoun SD, Fong TL, Vierling JM, Busuttil RW, Demetriou AA. Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver. Transplant Proc. 1997 Feb-Mar; 29(1-2):487-8. PMID: 9123096.
      Citations: 4     Fields:    Translation:HumansAnimals
    172. Trépo C, Vierling J, Zeytin FN, Gerlich WH. The first Flaviviridae symposium. Intervirology. 1997; 40(4):279-88. PMID: 9612731.
      Citations:    Fields:    Translation:HumansAnimalsCells
    173. Vierling JM, Villamil FG, Rojter SE, Camacho KB, Goldman DE. Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. J Viral Hepat. 1997; 4 Suppl 1:117-24. PMID: 9097290.
      Citations: 3     Fields:    Translation:Humans
    174. Geller SA, Nichols WS, Rojter SE, Chan RC, Petrovic LM, Vierling JM, Makowka L. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov; 27(11):1161-5. PMID: 8912825.
      Citations: 3     Fields:    Translation:HumansCells
    175. Villamil FG, Hu KQ, Yu CH, Lee CH, Rojter SE, Podesta LG, Makowka L, Geller SA, Vierling JM. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology. 1995 Nov; 22(5):1379-86. PMID: 7590651.
      Citations: 3     Fields:    Translation:HumansCells
    176. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995 Nov; 127(5):815-8. PMID: 7472844.
      Citations: 4     Fields:    Translation:Humans
    177. Silverman JM, Podesta L, Villamil F, Sher L, Vierling J, Rojter S, Hoffman A, Lopez R, Rosenthal P, Woolf G, et al. Portal vein patency in candidates for liver transplantation: MR angiographic analysis. Radiology. 1995 Oct; 197(1):147-52. PMID: 7568813.
      Citations: 1     Fields:    Translation:Humans
    178. Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: insights into management. Liver Transpl Surg. 1995 Sep; 1(5 Suppl 1):89-99. PMID: 9346605.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    179. Rojter S, Villamil FG, Petrovic LM, Silverman JM, Woolf GM, Podesta LG, Makowka L, Vierling JM. Malignant vascular tumors of the liver presenting as liver failure and portal hypertension. Liver Transpl Surg. 1995 May; 1(3):156-61. PMID: 9346558.
      Citations: 1     Fields:    Translation:Humans
    180. Hu KQ, Yu CH, Lee S, Villamil FG, Vierling JM. Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one-step polymerase chain reaction technique. Hepatology. 1995 Apr; 21(4):901-7. PMID: 7705799.
      Citations: 4     Fields:    Translation:HumansCells
    181. Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, Michieletti P, Wanless IR, Stermitz FR, Beck JJ, Vierling JM. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med. 1994 Nov 15; 121(10):729-35. PMID: 7944049.
      Citations: 29     Fields:    Translation:Humans
    182. Hu KQ, Vierling JM. Molecular diagnostic techniques for viral hepatitis. Gastroenterol Clin North Am. 1994 Sep; 23(3):479-98. PMID: 7989090.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    183. Woolf GM, Petrovic LM, Rojter SE, Villamil FG, Makowka L, Podesta LG, Sher LS, Memsic L, Vierling JM. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci. 1994 Jun; 39(6):1351-8. PMID: 8200270.
      Citations: 11     Fields:    Translation:Humans
    184. Hu KQ, Yu CH, Vierling JM. One-step RNA polymerase chain reaction for detection of hepatitis C virus RNA. Hepatology. 1993 Aug; 18(2):270-4. PMID: 7687979.
      Citations: 4     Fields:    Translation:HumansCells
    185. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis. 1993 Aug; 13(3):261-75. PMID: 8235716.
      Citations: 16     Fields:    Translation:Humans
    186. Hu KQ, Yu CH, Vierling JM. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc Natl Acad Sci U S A. 1992 Dec 01; 89(23):11441-5. PMID: 1360668.
      Citations: 12     Fields:    Translation:HumansCells
    187. Vierling JM. Immune disorders of the liver and bile duct. Gastroenterol Clin North Am. 1992 Jun; 21(2):427-49. PMID: 1512050.
      Citations: 2     Fields:    Translation:HumansCells
    188. Hu KQ, Yu CH, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J Clin Invest. 1992 Jun; 89(6):2040-5. PMID: 1318328.
      Citations: 4     Fields:    Translation:HumansCells
    189. Vierling JM. Immunologic mechanisms of hepatic allograft rejection. Semin Liver Dis. 1992 Feb; 12(1):16-27. PMID: 1570548.
      Citations: 4     Fields:    Translation:HumansCells
    190. Peters M, Vierling J, Gershwin ME, Milich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology. 1991 May; 13(5):977-94. PMID: 2030002.
      Citations: 27     Fields:    Translation:HumansAnimals
    191. Howell CD, Yoder TD, Vierling JM. Suppressor function of hepatic mononuclear inflammatory cells during murine chronic graft-vs-host disease. I. Macrophage-enriched cells mediate suppression in the liver. Cell Immunol. 1991 Jan; 132(1):256-68. PMID: 1829654.
      Citations: 1     Fields:    Translation:AnimalsCells
    192. Hu KQ, Vierling JM, Siddiqui A. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci U S A. 1990 Sep; 87(18):7140-4. PMID: 2169620.
      Citations: 24     Fields:    Translation:HumansCells
    193. Vierling JM, Howell CD. Disappearing bile ducts: immunologic mechanisms. Hosp Pract (Off Ed). 1990 Jul 15; 25(7):141-50. PMID: 2115531.
      Citations: 3     Fields:    Translation:HumansCells
    194. Gholson CF, Siddiqui A, Vierling JM. Cell surface expression of hepatitis B surface and core antigens in transfected rat fibroblast cell lines. Gastroenterology. 1990 Apr; 98(4):968-75. PMID: 2179036.
      Citations: 1     Fields:    Translation:AnimalsCells
    195. Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol. 1989 Jul 15; 143(2):476-83. PMID: 2472440.
      Citations: 6     Fields:    Translation:AnimalsCells
    196. Vierling JM. Biliary victories: studies of isolated biliary epithelial cells. J Lab Clin Med. 1989 Jun; 113(6):663-4. PMID: 2732615.
      Citations:    Fields:    Translation:HumansAnimalsCells
    197. Mizuno M, Yamada G, Sugiyama T, Vierling JM, Brown WR. Monoclonal antibodies identifying antigens on distinct domains of rat hepatocytes. Liver. 1987 Oct; 7(5):251-9. PMID: 3695813.
      Citations:    Fields:    Translation:AnimalsCells
    198. Berry WR, Gottesfeld RL, Alter HJ, Vierling JM. Transmission of hepatitis B virus by artificial insemination. JAMA. 1987 Feb 27; 257(8):1079-81. PMID: 3806899.
      Citations: 6     Fields:    Translation:Humans
    199. Fennell RH, Vierling JM. Electron microscopy of rejected human liver allografts. Hepatology. 1985 Nov-Dec; 5(6):1083-7. PMID: 3905559.
      Citations: 4     Fields:    Translation:HumansCells
    200. Finck MH, Reichen J, Vierling JM, Kloppel TM, Brown WR. Hepatic uptake and disposition of human polymeric IgA1 in perfused rat liver: evidence for incomplete biliary excretion and intrahepatic degradation. Am J Physiol. 1985 Apr; 248(4 Pt 1):G450-5. PMID: 3985150.
      Citations: 3     Fields:    Translation:HumansAnimals
    201. Mizuno M, Brown WR, Vierling JM. Ultrastructural immunocytochemical localization of the asialoglycoprotein receptor in rat hepatocytes. Gastroenterology. 1984 Oct; 87(4):763-9. PMID: 6088350.
      Citations: 5     Fields:    Translation:AnimalsCells
    202. Mizuno M, Kloppel TM, Nakane PK, Brown WR, Vierling JM. Cellular distribution of the asialoglycoprotein receptor in rat liver. Implications for hepatic accumulation of desialylated lymphocytes. Gastroenterology. 1984 Jan; 86(1):142-9. PMID: 6315523.
      Citations: 4     Fields:    Translation:AnimalsCells
    203. Vierling JM. Hepatic injury by prescription medication. Med Sect Proc. 1983; 79-86. PMID: 6678434.
      Citations:    Fields:    Translation:Humans
    204. Fennell RH, Shikes RH, Vierling JM. Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft. Hepatology. 1983 Jan-Feb; 3(1):84-9. PMID: 6295909.
      Citations: 7     Fields:    Translation:Humans
    205. Vierling JM, Berk PD, Hofmann AF, Martin JF, Wolkoff AW, Scharschmidt BF. Normal fasting-state levels of serum cholyl-conjugated bile acids in Gilbert's syndrome: an aid to the diagnosis. Hepatology. 1982 May-Jun; 2(3):340-3. PMID: 7076117.
      Citations: 3     Fields:    Translation:Humans
    206. Vierling JM. Copper metabolism in primary biliary cirrhosis. Semin Liver Dis. 1981 Nov; 1(4):293-308. PMID: 7051310.
      Citations: 1     Fields:    Translation:Humans
    207. James SP, Vierling JM, Strober W. The role of the immune response in the pathogenesis of primary biliary cirrhosis. Semin Liver Dis. 1981 Nov; 1(4):322-37. PMID: 7051311.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    208. Berk PD, Berman MD, Blitzer BL, Chretien P, Martin JF, Scharschmidt BF, Vierling JM, Wolkoff AW, Vergalla J, Waggoner JG. Effect of splenectomy of hepatic bilirubin clearance in patients with hereditary spherocytosis. Implications for the diagnosis of Gilbert's syndrome. J Lab Clin Med. 1981 Jul; 98(1):37-45. PMID: 7252326.
      Citations: 1     Fields:    Translation:Humans
    209. Steer CJ, James SP, Vierling JM, Hosea SW, Jones EA. The selective hepatic uptake of desialylated peripheral blood mononuclear cells in rabbits. Gastroenterology. 1980 Nov; 79(5 Pt 1):917-23. PMID: 7419016.
      Citations: 1     Fields:    Translation:AnimalsCells
    210. Jones EA, Vierling JM, Steer CJ, Reichen J. Cell surface receptors in the liver. Prog Liver Dis. 1979; 6:43-80. PMID: 396566.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    211. Jaffe CJ, Vierling JM, Jones EA, Lawley TJ, Frank MM. Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest. 1978 Nov; 62(5):1069-77. PMID: 711852.
      Citations: 32     Fields:    Translation:HumansCells
    212. Vierling JM, Steer CJ, Hickman JW, James SP, Jones EA. Cell-mediated cytotoxicity of desialylated human lymphocytes induced by a mitogenic mammalian liver protein. Gastroenterology. 1978 Sep; 75(3):456-61. PMID: 680501.
      Citations: 1     Fields:    Translation:AnimalsCells
    213. Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med. 1978 Aug; 55(2):139-48. PMID: 307998.
      Citations: 12     Fields:    Translation:Humans
    214. Vierling JM, Shrager R, Rumble WF, Aamodt R, Berman MD, Jones EA. Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson's disease. Gastroenterology. 1978 Apr; 74(4):652-60. PMID: 631501.
      Citations: 2     Fields:    Translation:Humans
    215. Vierling JM, Steer CJ, Bundy BM, Strober W, Jones EA, Hague NE, Nelson DL. Studies of complement receptors on cytotoxic effector cells in human peripheral blood. Cell Immunol. 1978 Feb; 35(2):403-13. PMID: 620434.
      Citations: 3     Fields:    Translation:HumansCells
    216. Martin JF, Vierling JM, Wolkoff AW, Scharschmidt BF, Vergalla J, Waggoner JG, Berk PD. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology. 1976 Mar; 70(3):385-91. PMID: 814028.
      Citations: 14     Fields:    Translation:HumansCells
    217. Gardner KD, Vierling JM. Solids, water, and solutes in papillary region of the rat kidney. Am J Physiol. 1969 Jul; 217(1):58-64. PMID: 5785900.
      Citations: 8     Fields:    Translation:Animals
    218. Vierling J, Roberts JL, Conway G, Heazlitt R. Effect on cardiac myosin of diverse methods of preparation. Biochim Biophys Acta. 1968 May 06; 160(1):53-62. PMID: 4231409.
      Citations: 1     Fields:    Translation:AnimalsCells
    VIERLING's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (714)
    Explore
    _
    Co-Authors (52)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _